MD4760B1 - Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D - Google Patents
Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D Download PDFInfo
- Publication number
- MD4760B1 MD4760B1 MDA20170014A MD20170014A MD4760B1 MD 4760 B1 MD4760 B1 MD 4760B1 MD A20170014 A MDA20170014 A MD A20170014A MD 20170014 A MD20170014 A MD 20170014A MD 4760 B1 MD4760 B1 MD 4760B1
- Authority
- MD
- Moldova
- Prior art keywords
- hepatitis
- compositions
- treatment
- methods
- virus
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000029570 hepatitis D virus infection Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 108700024845 Hepatitis B virus P Proteins 0.000 abstract 1
- 208000037262 Hepatitis delta Diseases 0.000 abstract 1
- 241000724709 Hepatitis delta virus Species 0.000 abstract 1
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- 150000004697 chelate complex Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Invenţia se referă la compoziţii şi metode de tratament al infecţiilor provocate de virusul hepatitei B sau de co-infecţia cu virusul hepatitei B şi virusul hepatitei D, care includ administrarea unui subiect ce are nevoie de un astfel de tratament al unui prim agent farmaceutic acceptabil, care conţine un complex chelat al cel puţin unui polimer al acidului nucleic tiofosfat şi al doilea agent farmaceutic acceptabil, care conţine cel puţin un analog nucleozidic/nucleotidic, care inhibă polimerazele HVB.Secvenţe: 20
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022846P | 2014-07-10 | 2014-07-10 | |
| US201462091943P | 2014-12-15 | 2014-12-15 | |
| PCT/CA2015/050626 WO2016004525A1 (en) | 2014-07-10 | 2015-07-07 | Methods for the treatment of hepatitis b and hepatitis d virus infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20170014A2 MD20170014A2 (ro) | 2017-07-31 |
| MD4760B1 true MD4760B1 (ro) | 2021-07-31 |
| MD4760C8 MD4760C8 (ro) | 2022-02-28 |
Family
ID=55063440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20170014A MD4760C8 (ro) | 2014-07-10 | 2015-07-07 | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9603865B2 (ro) |
| EP (1) | EP3166615B1 (ro) |
| JP (2) | JP2017521433A (ro) |
| KR (2) | KR102734495B1 (ro) |
| CN (2) | CN106659730A (ro) |
| AU (1) | AU2015286199B2 (ro) |
| BR (1) | BR112017000320B1 (ro) |
| CA (1) | CA2954182C (ro) |
| CL (1) | CL2017000008A1 (ro) |
| CU (1) | CU20170001A7 (ro) |
| DK (1) | DK3166615T3 (ro) |
| DO (1) | DOP2017000002A (ro) |
| EA (1) | EA036745B1 (ro) |
| EC (1) | ECSP16097355A (ro) |
| ES (1) | ES2963814T3 (ro) |
| FI (1) | FI3166615T3 (ro) |
| HK (1) | HK1231402A1 (ro) |
| HR (1) | HRP20231400T1 (ro) |
| HU (1) | HUE064449T2 (ro) |
| IL (1) | IL249660B (ro) |
| LT (1) | LT3166615T (ro) |
| MD (1) | MD4760C8 (ro) |
| MX (1) | MX381042B (ro) |
| MY (1) | MY178087A (ro) |
| PH (1) | PH12017500010B1 (ro) |
| PL (1) | PL3166615T3 (ro) |
| PT (1) | PT3166615T (ro) |
| RS (1) | RS64833B1 (ro) |
| SG (1) | SG11201700073PA (ro) |
| SI (1) | SI3166615T1 (ro) |
| SM (1) | SMT202300380T1 (ro) |
| TW (1) | TWI766831B (ro) |
| WO (1) | WO2016004525A1 (ro) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3853240A4 (en) * | 2018-11-08 | 2022-11-30 | Aligos Therapeutics, Inc. | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021119325A1 (en) * | 2019-12-12 | 2021-06-17 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CN113637030A (zh) * | 2020-05-07 | 2021-11-12 | 西安新通药物研究股份有限公司 | 甲磺酸帕拉德福韦b晶型及其应用 |
| WO2021223398A1 (zh) * | 2020-05-07 | 2021-11-11 | 西安新通药物研究股份有限公司 | 治疗肝病的晶型及其应用 |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| EP4247393A4 (en) * | 2020-11-20 | 2024-12-25 | Aligos Therapeutics, Inc. | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS WITH ENHANCED LIVER TARGETING |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| WO2022261046A1 (en) * | 2021-06-07 | 2022-12-15 | Antios Therapeutics, Inc. | Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs |
| EP4367241A1 (en) | 2021-07-09 | 2024-05-15 | GlaxoSmithKline Intellectual Property (No.3) Limited | Use of oligonucleotides for individuals with renal impairment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| JP2005538186A (ja) | 2002-09-13 | 2005-12-15 | レプリコール インコーポレーティッド | 非配列相補性の抗ウイルス性オリゴヌクレオチド |
| US9474793B2 (en) * | 2005-02-22 | 2016-10-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus |
| PL2605794T3 (pl) | 2010-08-20 | 2017-01-31 | Replicor Inc. | Chelatowe kompleksy oligonukleotydów |
| DK2632472T3 (en) * | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| AU2013262416B2 (en) * | 2012-05-18 | 2017-05-11 | Replicor Inc. | Oligonucleotide chelate complex-polypeptide compositions and methods |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| CA2883785C (en) * | 2012-08-30 | 2020-08-18 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2015
- 2015-07-07 BR BR112017000320-1A patent/BR112017000320B1/pt not_active IP Right Cessation
- 2015-07-07 DK DK15818148.7T patent/DK3166615T3/da active
- 2015-07-07 KR KR1020237015821A patent/KR102734495B1/ko active Active
- 2015-07-07 CA CA2954182A patent/CA2954182C/en active Active
- 2015-07-07 SM SM20230380T patent/SMT202300380T1/it unknown
- 2015-07-07 LT LTEPPCT/CA2015/050626T patent/LT3166615T/lt unknown
- 2015-07-07 EP EP15818148.7A patent/EP3166615B1/en active Active
- 2015-07-07 PL PL15818148.7T patent/PL3166615T3/pl unknown
- 2015-07-07 JP JP2017501004A patent/JP2017521433A/ja active Pending
- 2015-07-07 MY MYPI2017700005A patent/MY178087A/en unknown
- 2015-07-07 CN CN201580037179.0A patent/CN106659730A/zh active Pending
- 2015-07-07 PT PT158181487T patent/PT3166615T/pt unknown
- 2015-07-07 MD MDA20170014A patent/MD4760C8/ro active IP Right Grant
- 2015-07-07 HU HUE15818148A patent/HUE064449T2/hu unknown
- 2015-07-07 KR KR1020177003538A patent/KR20170029577A/ko not_active Ceased
- 2015-07-07 WO PCT/CA2015/050626 patent/WO2016004525A1/en not_active Ceased
- 2015-07-07 FI FIEP15818148.7T patent/FI3166615T3/fi active
- 2015-07-07 PH PH1/2017/500010A patent/PH12017500010B1/en unknown
- 2015-07-07 HR HRP20231400TT patent/HRP20231400T1/hr unknown
- 2015-07-07 SG SG11201700073PA patent/SG11201700073PA/en unknown
- 2015-07-07 ES ES15818148T patent/ES2963814T3/es active Active
- 2015-07-07 MX MX2017000053A patent/MX381042B/es unknown
- 2015-07-07 EA EA201790160A patent/EA036745B1/ru unknown
- 2015-07-07 HK HK17105180.0A patent/HK1231402A1/zh unknown
- 2015-07-07 SI SI201531976T patent/SI3166615T1/sl unknown
- 2015-07-07 AU AU2015286199A patent/AU2015286199B2/en not_active Ceased
- 2015-07-07 CN CN202111146395.2A patent/CN113750112A/zh active Pending
- 2015-07-07 RS RS20231031A patent/RS64833B1/sr unknown
- 2015-07-08 US US14/794,129 patent/US9603865B2/en not_active Expired - Fee Related
- 2015-07-13 TW TW104122636A patent/TWI766831B/zh active
-
2016
- 2016-12-20 IL IL249660A patent/IL249660B/en unknown
-
2017
- 2017-01-03 CL CL2017000008A patent/CL2017000008A1/es unknown
- 2017-01-03 DO DO2017000002A patent/DOP2017000002A/es unknown
- 2017-01-03 EC ECIEPI201697355A patent/ECSP16097355A/es unknown
- 2017-01-05 CU CUP2017000001A patent/CU20170001A7/es unknown
-
2020
- 2020-04-20 JP JP2020074639A patent/JP6922030B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4760B1 (ro) | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
| PH12017500614A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| ZA201901061B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| MX2021006635A (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas. | |
| PH12018500931A1 (en) | Hcv polymerase inhibitors | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| SG11201801809VA (en) | Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method | |
| WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
| MX373703B (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| MX2016002586A (es) | Métodos y composiciones para el tratamiento guiado por rna de infección por hiv. | |
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| MX2018002707A (es) | Derivados de tetrahidrofurano antivirales. | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| EP3271371A4 (en) | Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c | |
| MA40218A (fr) | Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d | |
| NZ727583B2 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| HK40008711A (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| WO2015177331A3 (en) | Nucleic acids acting as decoys for the treatment of lentivirus infection | |
| EA202090046A1 (ru) | Прицельная безвирусная вставка днк |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| TK4A | Erratum in official gazette in regard to patent for invention |
Free format text: RECTIFICATION IN INID 30 |